Natixis’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-51,038
| Closed | -$4.59M | – | 1354 |
|
|
2025
Q4 | $4.59M | Buy |
51,038
+41,395
| +429% | +$3.93M | 0.02% | 483 |
|
|
2025
Q3 | $950K | Buy |
+9,643
| New | +$956K | ﹤0.01% | 679 |
|
|
2025
Q2 | – | Sell |
-19,129
| Closed | -$2.15M | – | 1190 |
|
|
2025
Q1 | $2.15M | Sell |
19,129
-102,814
| -84% | -$11M | 0.01% | 415 |
|
|
2024
Q4 | $12.9M | Buy |
+121,943
| New | +$13.1M | 0.08% | 185 |
|
|
2024
Q3 | – | Sell |
-19,028
| Closed | -$2.07M | – | 1146 |
|
|
2024
Q2 | $2.07M | Sell |
19,028
-84,011
| -82% | -$9.9M | 0.01% | 407 |
|
|
2024
Q1 | $13.6M | Buy |
+103,039
| New | +$12.9M | 0.07% | 188 |
|
|
2023
Q4 | – | Sell |
-113,729
| Closed | -$12.8M | – | 1195 |
|
|
2023
Q3 | $12.8M | Buy |
113,729
+100,916
| +788% | +$12.8M | 0.1% | 170 |
|
|
2023
Q2 | $1.87M | Buy |
12,813
+5,974
| +87% | +$812K | 0.02% | 438 |
|
|
2023
Q1 | $884K | Sell |
6,839
-21,576
| -76% | -$2.71M | 0.01% | 544 |
|
|
2022
Q4 | $3.62M | Buy |
28,415
+15,255
| +116% | +$1.77M | 0.02% | 436 |
|
|
2022
Q3 | $1.38M | Buy |
13,160
+4,055
| +45% | +$445K | 0.01% | 687 |
|
|
2022
Q2 | $957K | Sell |
9,105
-300,335
| -97% | -$35.6M | ﹤0.01% | 831 |
|
|
2022
Q1 | $39.6M | Buy |
+309,440
| New | +$37.3M | 0.14% | 158 |
|
|
2021
Q4 | – | Sell |
-2,735
| Closed | -$389K | – | 1376 |
|
|
2021
Q3 | $389K | Buy |
+2,735
| New | +$402K | ﹤0.01% | 1056 |
|
|
2021
Q2 | – | Sell |
-5,019
| Closed | -$780K | – | 1145 |
|
|
2021
Q1 | $780K | Sell |
5,019
-130,743
| -96% | -$20.3M | ﹤0.01% | 883 |
|
|
2020
Q4 | $20.3M | Buy |
+135,762
| New | +$19.2M | 0.07% | 251 |
|
|
2020
Q3 | – | Sell |
-30,695
| Closed | -$3.56M | – | 888 |
|
|
2020
Q2 | $3.56M | Sell |
30,695
-71,945
| -70% | -$8.29M | 0.03% | 339 |
|
|
2020
Q1 | $10.1M | Buy |
102,640
+92,800
| +943% | +$12.2M | 0.08% | 194 |
|
|
2019
Q4 | $1.42M | Buy |
+9,840
| New | +$1.36M | 0.01% | 607 |
|
|
2019
Q3 | – | Sell |
-5,573
| Closed | -$637K | – | 939 |
|
|
2019
Q2 | $637K | Buy |
+5,573
| New | +$653K | ﹤0.01% | 581 |
|
|
2019
Q1 | – | Sell |
-284,599
| Closed | -$28.7M | – | 903 |
|
|
2018
Q4 | $28.7M | Buy |
284,599
+280,482
| +6,813% | +$31.5M | 0.24% | 110 |
|
|
2018
Q3 | $525K | Sell |
4,117
-151,438
| -97% | -$18M | ﹤0.01% | 628 |
|
|
2018
Q2 | $16.8M | Buy |
155,555
+31,918
| +26% | +$3.47M | 0.09% | 207 |
|
|
2018
Q1 | $13.1M | Buy |
123,637
+113,567
| +1,128% | +$13.2M | 0.08% | 224 |
|
|
2017
Q4 | $1.18M | Buy |
+10,070
| New | +$1.14M | 0.01% | 477 |
|
|
2017
Q3 | – | Sell |
-24,295
| Closed | -$3.03M | – | 1374 |
|
|
2017
Q2 | $3.03M | Buy |
24,295
+12,918
| +114% | +$1.53M | 0.03% | 289 |
|
|
2017
Q1 | $1.35M | Sell |
11,377
-5,520
| -33% | -$626K | 0.02% | 357 |
|
|
2016
Q4 | $1.69M | Buy |
+16,897
| New | +$1.81M | 0.02% | 379 |
|
Other funds holding ZBH
Natixis's ZBH Position: Q1 2026 in Review
Natixis sold out of Zimmer Biomet (ZBH) in Q1 2026, closing a stake of 51,038 shares — an estimated $4.59M sold.
Natixis first reported a position in ZBH in Q4 2016 and held it in 28 quarters. The position peaked at $39.6M in Q1 2022. 916 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Natixis reported no remaining Zimmer Biomet position as of Q1 2026 after selling out during the quarter.
- Natixis sold 51,038 Zimmer Biomet shares in Q1 2026, an estimated $4.59M.
- Natixis first reported a position in Zimmer Biomet in Q4 2016 and held it in 28 quarters.
- Natixis's Zimmer Biomet position peaked at $39.6M in Q1 2022.
- 916 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.